A Phase I/II Study Exploring the Safety and Activity of Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients
Latest Information Update: 12 Jun 2025
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms TriComB
Most Recent Events
- 06 Jun 2025 Planned End Date changed from 1 May 2025 to 1 Dec 2025.
- 17 Jan 2025 Planned End Date changed from 1 Mar 2025 to 1 May 2025.
- 11 Sep 2024 Status changed from recruiting to active, no longer recruiting.